Skip to main content

Does Mavyret cure hep C (HCV)? What is the success rate?

Medically reviewed by Melisa Puckey, BPharm. Last updated on July 12, 2024.

Official answer

by Drugs.com

Does Mavyret cure hepatitis C (HCV)? What is the success rate?

Yes, Mavyret is a treatment that can clinically cure hepatitis C viral infection (HCV).
The success rate for curing hepatitis C with Mavyret ranges from 95 to 99%.

How successful Mavyret (glecaprevir and pibrentasvir) is at treating hepatitis C depends on the:

  • form (or genotype) of hepatitis C
  • if you have cirrhosis of the liver, and at what stage your cirrhosis is
  • if you have already have or have not had treatment for hepatitis C
  • If you have HIV as well as hepatitis C

Hepatitis C has 6 different forms (or genotypes) and each different form has a different success rate when treated with Mavyret.
Liver cirrhosis seems to make it harder to clear the hepatitis infection so if you have cirrhosis you may need to have a longer treatment of 12 weeks.

Clinical Trials of Mavyret


In the Mavyret clinical trials hepatitis C is considered to be clinically cured when the blood test measuring hepatitis C viral RNA comes back as less than 15 IU/mL. This blood test is done 12 weeks after finishing treatment. It is regarded that hepatitis C has relapsed when the blood test level of hepatitis C RNA is over 15IU/mL.
The results below are from clinical trials that included patients who had never had hepatitis C treatment and patients who had already tried hepatitis C treatments.

Success rate of Mavyret for hepatitis C: Table.

Patients without cirrhosis Patients with cirrhosis Patients with cirrhosis
Genotype Mavyret 8 week treatment Mavyret 8 week treatment Mavyret 12 week treatment
GT1 99% (348/351) 98% (226/231) 99% (89/90)
GT2 98% (193/197) 98% (26/26) 100% (31/31)
GT4 93% (43/46) 100% (13/13) 100% (16/16)
GT5 95% (21/22) 100% (1/1) 100% (5/5)
GT6 100% (65/65) 100% (9/9) 92% (12/13)


Genotype 3 is harder to clear than the other genotypes of hepatitis C. The clinical trials for genotype 3 used only patients who had previously not had any hepatitis C treatments, which you would expect to have a better response compared to other clinical trials that included both patients who had and had not had previous treatment. The patients in the genotype 3 trial also had no cirrhosis. The results for treatment for 8 week with Mavyret were 95% (149/157) and for the 12 week treatment was 95% (222/233).

Bottom Line:

  • Mavyret is an 8 to 12 week treatment for hepatitis C infection.
  • Mavyret success rate for curing hepatitis C is between 95 to 99%.
  • The success of Mavyret to cure hepatitis C is dependent on a number of factors including genotype of hepatitis C, whether or not you have cirrhosis, previous hepatitis C treatments and other medical conditions you may have.

Related questions

References

Read next

Can you drink alcohol while taking Mavyret?

Alcohol use in patients with hepatitis C virus (HCV) may result in a quicker progression to cirrhosis and liver cancer. Mavyret (glecaprevir-pibrentasvir) is used to treat patients with advancing HCV. Because there is a link between a more rapid progression of liver disease and the use of alcohol, clinicians typically suggest that all patients with HCV avoid alcohol use. Continue reading

Does Mavyret make your hair fall out?

Mavyret should not make your hair fall out and hair loss is not a known side effect of Mavyret and was not a reported in clinical trials of Mavyret. Medication blog sites about Mavyret also do not mention hair loss as a side effect. Continue reading

Is Mavyret better than Harvoni?

Mavyret is reported to have some advantages over Harvoni including the number of hepatitis C virus (HCV) genotypes it covers, the length of treatment required, and the cost of a course of treatment. Continue reading

Related medical questions

Drug information

Related support groups

Medical Disclaimer